留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

肝细胞性肝癌代谢组学研究进展

刘悦,  赵亮,  李燕,  朱臻宇,  柴逸峰

downloadPDF
文章导航 > 药学实践与服务  > 2013 >  31(2): 81-85
刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰. 肝细胞性肝癌代谢组学研究进展[J]. 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
引用本文: 刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰. 肝细胞性肝癌代谢组学研究进展[J]. 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu
LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
Citation: LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu

肝细胞性肝癌代谢组学研究进展

doi: 10.3969/j.issn.1006-0111.2013.02.001
  • 1.

    第二军医大学药学院药物分析教研室, 上海 200433

  • 2.

    第二军医大学附属东方肝胆外科医院药材科, 上海 200438

  • 3.

    中国人民解放军总后勤部郑常庄干部休养所, 北京 100141

Advances in metabonomics of hepatocellular carcinoma

  • 1.

    Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China

  • 3.

    Zhengchangzhuang Clinic, Logistics Department of PLA, Beijing 100141, China

  • 摘要: 肝细胞性肝癌(HCC) 是最常见的、发病率和死亡率较高的恶性肿瘤之一, 严重危害了人类的健康。代谢组学能够将高通量、高分辨率的分析技术与生物信息学相整合,对生物代谢层面进行研究, 为寻找早期诊断肝细胞性肝癌的生物标志物、探索HCC发生的机制提供独特的视角。本文对近年来肝细胞性肝癌代谢组学研究进展进行综述,为进一步深入研究提供参考。
    Abstract: Hepatocellular carcinoma (HCC) was one of the most common malignancies with high incidence and mortality which threatened human health. Integrating analytical technology of high throughput and high resolution with bioinformatics, metabonomics could investigate the organism on the level of metabolism, provide a unique insight into searching biomarkers for early diagnosis of HCC and exploring the mechanism of HCC. The advances of metabonomics studies on HCC in the recent years were reviewed in this paper which could provide the reference for further research.
  • [1] Hanahan D, Weinberg R. The hallmarks of cancer[J]. Cell, 2000, 100(1):57.
    [2] World Health Organization. mortality database, WHO statistical information system.available at http://www.who.int/whosis/en/.accessed March 19, 2008.
    [3] Kassahun W, Fangmann J, Harms J, et al. Liver Resection and Transplantation in the Management of Hepatocellular Carcinoma:A Review[J]. Exp Clin Transplant, 2006, 4(2):549.
    [4] El-Serag HB, Rudolph L. Hepatocellular carcinoma:Epidemiology and molecular carcinogenesis[J]. Gastroenterology, 2007, 132(7):2557.
    [5] Anthony P. Hepatocellular carcinoma:an overview[J]. Histopathology,2001, 39(2):109.
    [6] El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States[J]. New Eng J Med, 1999, 340(10):745.
    [7] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma[J]. Gastroenterology, 2004, 126(2):460.
    [8] El-Serag H, Mason A, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States[J]. Hepatology, 2001, 33(1):62.
    [9] Onodera H, Ukai K, Minami Y. Hepatocellular-Carcinoma Cases with 5-Year Survival and Prognostic Factors Affecting the Survival-Time[J]. Tohoku J Exp Med, 1995, 176(4):203.
    [10] Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast,and prostate cancer[J]. Science, 1997, 275(5308):1943.
    [11] Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocel lular carcinoma:correlation with proliferation. prognostic parameters,and outcome[J]. Modern Pathology, 2004, 17(11):1378.
    [12] Furui J, Furukawa M, Kanematsu T. The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma[J]. Hepatogastroenterology,1995, 42(5):445.
    [13] Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma[J]. J Clin Gastroenterol, 2002, 35(5 Suppl. 2):S86.
    [14] Peng YC, Chan CS, Chen GH. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma[J]. Hepatogastroenterology, 1999, 46(30):3208.
    [15] Nicholson J, Lindon J, Holmes E. 'Metabonomics':understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11):1181.
    [16] Fiehn O. Metabolomics—the link between genotypes and phenotypes[J]. Plant Mol Biol,2002, 48(1-2):155.
    [17] Zhang F, Jia Z, Gao P, et al. Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry[J]. Mol BioSyst, 2010, 6(5):852.
    [18] Chen Y, Zhang R, Song Y, et al. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network:finding potential biomarkers for breast cancer[J]. Analyst, 2009, 134(10):2003.
    [19] Zhou J, Xu B, Huang J, et al. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma[J]. Clinica Chimica Acta, 2009, 401(1-2):8.
    [20] Pasikanti KK, Esuvaranathan K, Ho PC, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer[J]. J Proteome Res, 2010, 9(6):2988.
    [21] Lindon J, Nicholson J, Holmes E. The handbook of metabonomics and metabolomics[M]. Amsterdam:elsevier BV,2007:201~226.
    [22] Schmidt C. Metabolomics takes its place as latest up-and-coming "omic" science[J]. J Natl Cancer Inst, 2004, 96(10):732.
    [23] Cao H, Huang H, Xu W, et al. Fecal metabolome pro?ling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry[J]. Analytica Chimica Acta, 2011, 691(1-2):68.
    [24] Yin P, Wan D, Zhao C, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry[J]. Mol BioSyst, 2009, 5(8):868.
    [25] Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling[J]. Cancer Res, 2011, 71(21):6590.
    [26] Gao H, Lu Q, Liu X, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis[J]. Cancer Sci,2009, 100(4):782.
    [27] Chen F, Xue J, Zhou L, et al. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method[J]. Anal Bioanal Chem, 2011, 401(6):1899.
    [28] Shariff MIF, Ladep NG, Cox IJ, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population[J]. J Proteome Res, 2010, 9(2):1096.
    [29] Shariff MIF, Gomaa AI, Cox IJ, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population:a validation study[J]. J Proteome Res, 2011, 10(4):1828.
    [30] Xue R, Lin Z, Deng C, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry[J]. Rapid Commun Mass Sp, 2008, 22(19):3061.
    [31] Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Mol Cell Proteomics, 2011, 10(7).
  • [1] 万立志, 王境焓, 吴春蓉, 李玲.  基于代谢组学技术的烟酰胺协同两性霉素B抑制白念珠菌的作用机制研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202307034
    [2] 何晓莉, 施艺玮, 王辉, 戴建英, 洪战英.  细胞代谢组学及其在中枢神经系统疾病研究的应用进展 . 药学实践与服务, 2023, 41(2): 63-69. doi: 10.12206/j.issn.2097-2024.202203006
    [3] 马小雨, 罗彩萍, 刘悦.  代谢组学在乳腺癌诊疗中应用的研究进展 . 药学实践与服务, 2023, 41(3): 139-145. doi: 10.12206/j.issn.2097-2024.202109112
    [4] 何永平, 焦杨, 刘悦.  胆管癌代谢组学研究进展 . 药学实践与服务, 2023, 41(12): 705-709, 732. doi: 10.12206/j.issn.2097-2024.202211025
    [5] 刘耀阳, 吴歆, 周凌, 赵颖, 徐沪济.  基于生物标志物探索系统性红斑狼疮中医药治疗机制的研究进展 . 药学实践与服务, 2023, 41(4): 197-201. doi: 10.12206/j.issn.2097-2024.202206131
    [6] 秦烨, 丁欣, 张雅.  参附汤抗阿霉素心肌病小鼠血清代谢组学研究 . 药学实践与服务, 2022, 40(2): 108-112. doi: 10.12206/j.issn.1006-0111.202105116
    [7] 陶朝阳, 朱臻宇, 邢心睿, 曹奇, 王辉.  基于LC-MS技术的二氢丹参酮Ⅰ抗肝纤维化肝脏代谢组学研究 . 药学实践与服务, 2021, 39(5): 403-408, 471. doi: 10.12206/j.issn.1006-0111.202101035
    [8] 赵景昕, 缪朝玉, 徐添颖.  脓毒症生物标志物的最新进展 . 药学实践与服务, 2021, 39(6): 491-498. doi: 10.12206/j.issn.1006-0111.202105040
    [9] 郑约楠, 邵国建, 张一帆, 邵玲就, 周琪, 司亚晨.  黄连提取物减轻脓毒症相关急性肾损伤的代谢组学研究 . 药学实践与服务, 2020, 38(5): 435-440. doi: 10.12206/j.issn.1006-0111.202003127
    [10] 杜毅, 丁德英, 吕磊, 李玲.  基于GC-MS技术的金钱草干预结晶肾损伤小鼠血清代谢组学研究 . 药学实践与服务, 2019, 37(4): 332-336. doi: 10.3969/j.issn.1006-0111.2019.04.009
    [11] 王学雷, 晁玉凡, 高松燕, 董昕, 温晓飞.  基于UPLC-Q-TOF/MS平台的结晶肾损伤小鼠的尿液代谢组学研究 . 药学实践与服务, 2019, 37(2): 126-134. doi: 10.3969/j.issn.1006-0111.2019.02.006
    [12] 宋志强, 朱臻宇, 刘悦, 柴逸峰.  代谢组学在白血病中的研究进展 . 药学实践与服务, 2019, 37(5): 385-389,399. doi: 10.3969/j.issn.1006-0111.2019.05.001
    [13] 周倩, 刘奎, 马静, 谭光国.  芪附汤对大鼠抗阿霉素心脏毒性作用的血清气相色谱-质谱代谢组学研究 . 药学实践与服务, 2018, 36(4): 313-317. doi: 10.3969/j.issn.1006-0111.2018.04.006
    [14] 刘世钰, 赵亮, 陈俊, 张国庆.  基于组学技术的抑郁症相关生物标志物研究进展 . 药学实践与服务, 2018, 36(3): 198-203. doi: 10.3969/j.issn.1006-0111.2018.03.002
    [15] 贾雨婷, 靳雨晨, 谭光国.  四逆汤治疗甲状腺功能减退症的血清代谢组学研究 . 药学实践与服务, 2016, 34(3): 237-240,248. doi: 10.3969/j.issn.1006-0111.2016.03.011
    [16] 杨宇, 王慧, 曹颖瑛, 朱臻宇.  基于气相色谱-质谱技术对用咪康唑处理的白念珠菌的代谢组学研究 . 药学实践与服务, 2015, 33(3): 209-212. doi: 10.3969/j.issn.1006-0111.2015.03.005
    [17] 纪松岗, 吴琼, 朱臻宇, 董昕, 洪战英, 柴逸峰.  左卡尼汀缓解顺铂造成急性肾损伤的血清代谢组学研究 . 药学实践与服务, 2015, 33(5): 429-433. doi: 10.3969/j.issn.1006-0111.2015.05.012
    [18] 王彦, 俞仲望, 陈思, 李玲, 朱臻宇.  气相色谱-质谱联用结合代谢组学方法研究不同极化状态下小胶质细胞的代谢差异 . 药学实践与服务, 2015, 33(3): 226-230. doi: 10.3969/j.issn.1006-0111.2015.03.009
    [19] 王洁, 夏振娜, 车爱萍, 袁伯俊, 陆国才.  消化系统毒理学生物标志物研究新进展 . 药学实践与服务, 2011, 29(4): 247-250.
    [20] 蒋海强, 马斌, 聂磊, 李运伦.  高血压病肝阳上亢证患者血清样品的核磁共振谱代谢组学研究 . 药学实践与服务, 2010, 28(4): 258-261.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2853
  • HTML全文浏览量:  240
  • PDF下载量:  141
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-04-16
  • 修回日期:  2012-09-20

肝细胞性肝癌代谢组学研究进展

doi: 10.3969/j.issn.1006-0111.2013.02.001
  • 1. 第二军医大学药学院药物分析教研室, 上海 200433
  • 2. 第二军医大学附属东方肝胆外科医院药材科, 上海 200438
  • 3. 中国人民解放军总后勤部郑常庄干部休养所, 北京 100141
  • 收稿日期: 2012-04-16
  • 修回日期: 2012-09-20

摘要: 肝细胞性肝癌(HCC) 是最常见的、发病率和死亡率较高的恶性肿瘤之一, 严重危害了人类的健康。代谢组学能够将高通量、高分辨率的分析技术与生物信息学相整合,对生物代谢层面进行研究, 为寻找早期诊断肝细胞性肝癌的生物标志物、探索HCC发生的机制提供独特的视角。本文对近年来肝细胞性肝癌代谢组学研究进展进行综述,为进一步深入研究提供参考。

English Abstract

刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰. 肝细胞性肝癌代谢组学研究进展[J]. 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
引用本文: 刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰. 肝细胞性肝癌代谢组学研究进展[J]. 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu
LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
Citation: LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu

    全文HTML

参考文献 (31)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计